Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)January 15, 2008
Medicis Pharmaceutical Corporation
(Exact name of registrant as specified in its charter)
| Delaware (State of Incorporation) | 001-14471 (Commission File Number) | 52-1574808 (IRS Employer Identification Number) |
8125 North Hayden Road
Scottsdale, Arizona 85258-2463
(Address of principal executive offices) (Zip Code)
Scottsdale, Arizona 85258-2463
(Address of principal executive offices) (Zip Code)
(602) 808-8800
(Registrant’s telephone number, including area code)
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
| Item 8.01 Other Events. | ||||||||
| SIGNATURES | ||||||||
Table of Contents
| Item 8.01 | Other Events. |
Medicis Pharmaceutical Corporation (“Medicis”) today announced that IMPAX Laboratories, Inc. (“IMPAX”) has advised it by letter that IMPAX has filed an Abbreviated New Drug Application (“ANDA”) with the U.S. Food and Drug Administration (“FDA”) for a generic SOLODYN®. IMPAX has not advised Medicis as to the timing or status of the FDA’s review of its filing, or whether IMPAX has complied with recent FDA requirements for proving bioequivalence. In its letter, IMPAX makes no mention of Medicis’ numerous pending patent applications, and refers only to Medicis’ issued patent covering SOLODYN®, U.S. Patent No. 5,908,838. Medicis is evaluating IMPAX’s letter and considering its options.
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: January 15, 2008 | By: | /s/ Mark A. Prygocki, Sr. | ||
| Mark A. Prygocki, Sr. | ||||
| Executive Vice President, Chief Financial Officer and Treasurer | ||||